Polaroid Therapeutics
Ran Frenkel serves as the Chief Executive Officer of Polaroid Therapeutics since December 2022. Prior to this role, Ran was a member of the Advisory Board for Musli Thyropeutics Ltd., contributing to initiatives targeting aggressive cancers such as Glioblastoma Multiforme. Ran's extensive experience includes serving as Executive Vice President, Worldwide Development Operations, and Executive VP & Chief Development Officer at Karyopharm Therapeutics Inc. from October 2014 to December 2022. Additionally, Ran held positions such as Executive Board Member and Director of European Liaison at IISRA, Managing Director at Clinipace Worldwide, and Managing Director of Actelion Pharmaceuticals Israel. Earlier in the career, Ran directed the Clinical Research Center at Sheba Medical Center. Educational background includes a Bachelor of Pharmacy degree from The Hebrew University of Jerusalem.
This person is not in any teams
Polaroid Therapeutics
Polaroid Therapeutics, founded in 2022, is a healthcare company focused on developing innovative antimicrobial solutions for wound healing and additional indications with unmet medical needs. As a spinoff of Polaroid Sciences, our mission is to bring to life the best of Polaroid's vision of creating a more human and meaningful world through cutting-edge technology and research. Our proprietary technology is designed to address major challenges in antimicrobial therapies and improve patient outcomes. We are committed to positively impacting the lives of patients and their families by delivering superior treatments that prevent, heal, and improve the quality of life. We aspire to reach and help all humankind around the globe.